Research & Development
Now Recruiting Patients for a New FDA Oversight Trial Evaluating the Use of a Patient's Own Fat Tissue for the Treatment of Post-COVID-19 Lung Damage
18 November 2020 - - US-based medical devices and systems developer Tulip Medical (a dba of Black Tie Medical, Inc.) has sponsored and funded a new FDA Oversight Trial that seeks to restore respiratory function in adults who have suffered lung damage from the COVID-19 virus, the company said.

Robert W. Alexander, MD, DMD, FICS is the Principal Investigator, and his office is recruiting patients for enrollment in the trial.

More information about the protocols and merits of the study, as well as the research that has led to the FDA's oversight of a patient trial, is available on the San Diego Academy of Regenerative Therapies ( Online Learning Platform.

The Panel discussion recorded on October 1, 2020, features Dr. Alexander and Dr. Ramon Llull, MD, Ph.D., a research colleague who has done extensive studies on the use of cellular Stromal Vascular Fraction.

Tulip Medical is a subsidiary of SDARTs.

Patients considering participation in this clinical trial should email Dr. Alexander at
Watch the Panel Discussion Webinar with Dr. Alexander and Dr. Ramon Llull.

Read Dr. Alexander's newest article detailing the diagnostic and treatment protocol for this ground-breaking clinical trial in Stem Cell Research.

Read Dr. Llull's latest article characterizing adipose tissue's regenerative capabilities in the Journal of Plastic and Reconstructive Surgery.

Tulip Medical develops and markets medical devices and systems for using adipose tissue for plastic surgery, dermatology, regenerative medicine, and anti-aging patient applications.

Tulip holds numerous patents on medical devices and methods designed to help medical practitioners harness and deliver the benefits of fat to millions of patients.


Related Headlines